Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HNRNPD
REST API REST API
Homo sapiens
HNRNPD is differentially expressed in 397 experiments: 173 organism parts: bone marrow, liver, ... (171 more);, 311 disease states: normal, control, ... (309 more);, 137 cell types 540 cell lines 60 compound treatments and 87 other conditions.
Synonyms AUF1, HNRPD
Orthologs ENSCING00000003877 (Ciona intestinalis)   Q5ZIH1_CHICK (Gallus gallus)   ENSCING00000016737 (Ciona intestinalis)   Hnrnpd (Mus musculus)   A6H6Y0_BOVIN (Bos taurus)   HRP1 (Saccharomyces cerevisiae)   hnrnpd (Danio rerio)   Hnrpd (Rattus norvegicus)   sqd (Drosophila melanogaster)   hnrnpd (Xenopus laevis)   HNRNPD (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, RNA splicing, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, RNA processing, ribonucleoprotein complex, nucleic acid binding, RNA metabolic process, regulation of mRNA stability, nucleus, heterogeneous nuclear ribonucleoprotein complex, nucleotide binding, nuclear mRNA splicing, via spliceosome, nucleoplasm, telomeric DNA binding, positive regulation of transcription, DNA-dependent, RNA binding, mRNA stabilization, mRNA metabolic process, gene expression, RNA catabolic process
InterPro Term CARG-binding_factor_N, RRM_dom
UniProt Accession D6RD83, D6RBP9, D6RBQ9, D6RAF8, D6RF44, Q14103, B4DTC3, F5H6R6
Search EB-eye ENSG00000138668
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
H441
2
E-MTAB-62, E-GEOD-16194
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-GEOD-14990, E-TABM-420
534 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (62 experiments)

Factor Value U/D Experiments
centroblast
2
E-GEOD-15271, E-TABM-702
CD34+
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
fibroblast
2
E-GEOD-3920, E-GEOD-3204
macrophage
1
2
E-GEOD-22373, E-GEOD-3982, E-GEOD-8286
131 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-MEXP-2280, E-GEOD-16363, ... (80 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-6014, E-MTAB-37, E-GEOD-4290, E-MTAB-62, E-MEXP-567 ... (5 experiments)
sarcoma
3
E-GEOD-2719, E-MTAB-62, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
305 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (38 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-3284, E-GEOD-4006, E-GEOD-5339, E-GEOD-995
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
placebo
2
E-MEXP-1335, E-MEXP-1327
Cxcl12
1
E-GEOD-7307
54 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-GEOD-19348, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-16058, E-GEOD-20033, E-GEOD-3140, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (11 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-1956, E-MEXP-2069, ... (44 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-TABM-585, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-3494, E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.456 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM